Agenus reports third quarter 2023 results

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the third quarter 2023. agenus executives will host a conference call and webcast at 9:00 a.m. et to discuss the results and to provide a corporate update. key highlights include: recent data shows that botensilimab (bot), with or without balstilimab (bal), is broadly effective in treating five advanced.
AGEN Ratings Summary
AGEN Quant Ranking